CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 ...

My relationship with lymphedema has been more complicated than my relationship with the mastectomy. While I am less stressed ...

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, ...

Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus ...

Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or ...

An expert explains that the GAP regimen did not improve overall survival in advanced biliary tract cancer versus the doublet ...

The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous ...

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive ...